New biosensors for managing microbial ‘workers’
Date: Aug 4, 2015
Researchers at Harvard’s Wyss Institute have unveiled new biosensors that enable scientists to more effectively control and 'communicate with' engineered bacteria
Super productive factories of the future could employ fleets of genetically engineered bacterial cells, such as common E. coli, to produce valuable chemical commodities in an environmentally friendly way. By leveraging their natural metabolic processes, bacteria could be re–programmed to convert readily available sources of natural energy into pharmaceuticals, plastics and fuel products.
New biosensors developed by Wyss Institute Core Faculty member George Church enable complex genetic re–programming of common bacteria like E. coli and could be leveraged for sustainable biomanufacturing, using the metabolic processes of bacterial cells to generate valuable chemicals and fuels. Credit: Alexey Romanenko/Depositphotos.com
"The basic idea is that we want to accelerate evolution to make awesome amounts of valuable chemicals," said Wyss Core Faculty member George Church, Ph.D., who is a pioneer in the converging fields of synthetic biology, metabolic engineering, and genetics. Church is the Robert Winthrop Professor of Genetics at Harvard Medical School and Professor of Health Sciences and Technology at Harvard and MIT.
Critical to this process of metabolically engineering microbes is the use of biosensors. Made of a biological component — such as a fluorescent protein — and a 'detector' that responds to the presence of a specific chemical, biosensors act as the switches and levers that turn programmed functions on and off inside the engineered cells. They also can be used to detect which microbial 'workers' are producing the most voluminous amounts of a desired chemical. In this way, they can be thought of as the medium for two–way communication between humans and cells.
But so far, scientists have only had access to a limited variety of biosensors that have little relevance to the bio–manufacturing of valuable chemicals. Now, Wyss Institute researchers led by Church have developed a new suite of such sensors, reported in Nucleic Acids Research journal, that not only increase the number of cellular "switches and levers" that scientists can use for complex genetic re–programming, but also respond to valuable products such as renewable plastics or costly pharmaceuticals and give microbes a voice to report on their own efficiency in making these products.
"We can communicate with cells much more effectively, and vice versa," said the study’s first author Jameson Rogers, a graduate researcher at the Wyss Institute who is pursuing his Ph.D. in Engineering Sciences from Harvard University. "If we compared this to controlling a computer, it’s almost like we have only had the up and down arrows available to us, and now suddenly we have doubled our control capabilities by adding the left and right arrows as well."
The Wyss team aims to leverage the new biosensors to aid in its efforts to develop renewable chemical production strategies using genetically engineered microbes.
Linked to green fluorescent protein (GFP), the biosensors can be used to trigger individual cells to give off visible fluorescence in a rate directly proportional to how well they are able to produce a desired chemical commodity. Using the new biosensors, the most efficient microbial workers are easily identified so that they can serve as the predecessors for colonies of engineered bacteria that evolve to become more efficient at producing renewable chemicals with each subsequent generation. This drastically reduces the bottleneck of the design–build–test cycle, which has historically been caused by engineers having to sift through teeming bacteria colonies to find top producers.
The findings could also lead to new applications in environmental monitoring using genetically engineered microbes to issue warning signals in the presence of pollutants or toxins, and could unlock new fundamental insights into metabolic pathways.
"Our team is developing several different ways to make even more custom biosensors," said Church. "We’re trying to control biological processes and we need new ways to get our hands in at the molecular level — we’re now reaching in deeper than we’ve previously been able to, and we still have many interesting new approaches."
"With this work, George and his team are bringing us closer to a sustainable future in which we would rely on bio–manufacturing for the clean production of chemical and pharmaceutical commodities," said Wyss Institute Founding Director Donald E. Ingber, M.D., Ph.D., who is also the Judah Folkman Professor of Vascular Biology at Harvard Medical School and Boston Children's Hospital, and Professor of Bioengineering at the Harvard John A. Paulson School of Engineering and Applied Sciences.
Wyss Institute for Biologically Inspired Engineering at Harvard University
Kat J. McAlpine, email@example.com, +1 617-432-8266
The Wyss Institute for Biologically Inspired Engineering at Harvard University (http://wyss.harvard.edu) uses Nature's design principles to develop bioinspired materials and devices that will transform medicine and create a more sustainable world. Wyss researchers are developing innovative new engineering solutions for healthcare, energy, architecture, robotics, and manufacturing that are translated into commercial products and therapies through collaborations with clinical investigators, corporate alliances, and formation of new start–ups. The Wyss Institute creates transformative technological breakthroughs by engaging in high risk research, and crosses disciplinary and institutional barriers, working as an alliance that includes Harvard's Schools of Medicine, Engineering, Arts & Sciences and Design, and in partnership with Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, Boston Children's Hospital, Dana–Farber Cancer Institute, Massachusetts General Hospital, the University of Massachusetts Medical School, Spaulding Rehabilitation Hospital, Boston University, Tufts University, and Charité – Universitätsmedizin Berlin, University of Zurich and Massachusetts Institute of Technology.